Moreover, the therapeutic dividend attributed to anaplastic lymphoma kinase (ALK) inhibitors (e.g., crizotinib, ceritinib, alectinib, and brigatinib) is confined to individuals harboring lung adenocarcinomas bearing the ALK fusions [19]. This evidence concerns the gene ALK and lung adenocarcinoma.